Cirrus Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-19.
Cirrus Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 19, 2025. The filing reports $6.70M sold. Its industry group is Other Technology. It names Ying Kai Chan (Executive Officer, Director, Promoter), Andrew Dick (Director, Promoter), Alexandra Cantley (Director) (SEC Form D, August 19, 2025).
Is this your company?
Sell to companies like Cirrus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cirrus Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Cirrus Therapeutics, Inc., from the filings we hold.
Other Technology raises by companies based in Massachusetts, filed in August 2025, largest first.
Get an email when Cirrus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cirrus Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cirrus Therapeutics, Inc. →Get the full cited report on Cirrus Therapeutics, Inc.
What the filing shows about Cirrus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cirrus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Cirrus Therapeutics, Inc.'s address as 750 Main Street, Cambridge, MA 02139.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Cirrus Therapeutics, Inc. See pricing
Cirrus Therapeutics, Inc. is a registered filer with the SEC (CIK 2078601) and has filed since 2025-08-19. 1 filing is on record, the latest on 2025-08-19.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cirrus Therapeutics, Inc.'s Form D of 2025-08-19 names Ying Kai Chan, Andrew Dick, Alexandra Cantley and 1 more as its officers, directors or promoters.
Its new offerings report $6.70M sold across 1 offering, as its own filings state.
Trailing twelve months. 3842 filings in Other Technology, totalled by week.
Ying Kai Chan is named as Executive Officer and Director and Promoter on the Form D that Cirrus Therapeutics, Inc. filed with the SEC on 19 August 2025, one of 4 people that filing names.
Andrew Dick is named as Director and Promoter on the Form D that Cirrus Therapeutics, Inc. filed with the SEC on 19 August 2025, one of 4 people that filing names.
Alexandra Cantley is named as Director on the Form D that Cirrus Therapeutics, Inc. filed with the SEC on 19 August 2025, one of 4 people that filing names.
Khoo Shih is named as Director on the Form D that Cirrus Therapeutics, Inc. filed with the SEC on 19 August 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-08-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cirrus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cirrus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cirrus Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cirrus Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Cirrus Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cirrus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cirrus-therapeutics-inc-form-d-25000001